4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
PegBio Co., Ltd. (2565) operates in the Biotechnology industry and is headquartered in Hangzhou, China with about 58 employees. Its market capitalization is roughly CNY 3 billion. In the fiscal year ended 2025-12-31, 2565 reported CNY 0M in revenue and (CNY 208M) in net income.
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | CNY 0M | CNY 0M | CNY 0M | CNY 0M |
| Gross Profit | CNY 0M | CNY 0M | — | — |
| Operating Income (EBIT) | (CNY 206M) | (CNY 288M) | (CNY 289M) | (CNY 318M) |
| Net Income | (CNY 208M) | (CNY 283M) | (CNY 279M) | (CNY 306M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | CNY 599M | CNY 218M | CNY 368M | CNY 438M |
| Total Liabilities | CNY 151M | CNY 161M | CNY 173M | CNY 132M |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2565 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms